Efficacy of Pregabalin for Peripheral Neuropathic Pain: Results of an 8-Week, Flexible-Dose, Double-Blind, Placebo-Controlled Study Conducted in China

Guan, Yuzhou; Ding, Xinyuan; Cheng, Yan; Fan, Dongsheng; Tan, Lan; Wang, Yongjun; Zhi-gang, Zhao; Hong, Zhen; Zhou, Dong; Pan, Xiaoping; Chen, Shengdi; Martin, Andrew; Tang, Haiyun; Cui, Liying

doi:10.1016/j.clinthera.2011.02.007

Cited by 58 publications

(35 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, pregabalin resulted in significantly greater improvements in SF‐MPQ VAS and PPI scores, sleep interference, sleep disturbance and quantity of sleep, together with overall significantly greater improvements in health status as measured by both PGIC and CGIC, compared with placebo. These results confirm and extend the findings of a previous study conducted in a mixed population of Chinese patients with either PHN or DPN in which pregabalin also resulted in significantly greater improvement in pain scores, SF‐MPQ VAS and PPI scores, sleep interference and PGIC and CGIC assessments in comparison to placebo …”

Section: Discussionsupporting

confidence: 90%

A Randomized, Double‐blind, Placebo‐controlled Trial to Evaluate the Efficacy and Safety of Pregabalin for Postherpetic Neuralgia in a Population of Chinese Patients

Liu

Chen

et al. 2015

Pain Practice

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

A Randomized, Double‐blind, Placebo‐controlled Trial to Evaluate the Efficacy and Safety of Pregabalin for Postherpetic Neuralgia in a Population of Chinese Patients

Liu

Chen

et al. 2015

Pain Practice

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, analysis of weekly pain scores showed a statistically significant improvement with pregabalin compared with placebo from week 7 to week 18, which was only lost at week 19 (endpoint) due to a gradual reduction in pain score for patients receiving placebo. Pregabalin was generally well tolerated, and the AE profile was consistent with previous double-blind, parallel group [15][16][17][18][19][20][21]45,46 and randomized withdrawal trials [25][26][27] of pregabalin for peripheral neuropathic pain.…”

Section: Discussionsupporting

confidence: 73%

Pregabalin in Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy

Raskin

Huffman

Toth

et al. 2014

The Clinical Journal of Pain

View full text Add to dashboard Cite

show abstract

“…In a separate trial, 52% of patients with baseline pain intensity in the high moderate to severe range had >50% relief compared to 24% in the placebo group over a 12 week RCT yielding a number needed to treat (NNT) of 3.6 138 . Similar positive results have been seen in PC-RCTs in China, Canada, Japan, Europe and Korea 137,179–182 . Subsequent RCTs found no improvement in pain intensity when using 150mg/daily 183 , 300mg/daily 184,185 but curiously patients in the lower dose groups had a significantly impression of improvement in their global well-being as compared to placebo 183 .…”

Section: Findings From Studies Grouped By Chronic Pain Syndromesupporting

confidence: 81%

Alternatives to Opioids in the Pharmacologic Management of Chronic Pain Syndromes: A Narrative Review of Randomized, Controlled, and Blinded Clinical Trials

Nicol

Hurley

Benzon

2017

Anesthesia &Amp; Analgesia

View full text Add to dashboard Cite

Chronic pain exerts a tremendous burden on individuals and societies. If one views chronic pain as a single disease entity, then it is the most common and costly medical condition. At present, medical professionals who treat patients in chronic pain are recommended to provide comprehensive and multidisciplinary treatments, which may include pharmacotherapy. Many providers employ non-opioid medications to treat chronic pain, however, for some patients, opioid analgesics are the exclusive treatment of chronic pain. However, there is currently an epidemic of opioid use in the United States, and recent guidelines from the Centers for Disease Control (CDC) have recommended that the use of opioids for non-malignant chronic pain be used only in certain circumstances. The goal of this review was to report the current body of evidence-based medicine gained from prospective, randomized-controlled, blinded studies on the use of non-opioid analgesics for the most common non-cancer chronic pain conditions. A total of 9566 studies were obtained during literature searches and 271 of these met inclusion for this review. Overall, while many non-opioid analgesics have been found to be effective in reducing pain for many chronic pain conditions, it is evident that the number of high-quality studies is lacking and the effect sizes noted in many studies is not considered to be clinically significant despite statistical significance. More research is needed to determine effective and mechanisms-based treatments for the chronic pain syndromes discussed in this review. Utilization of rigorous and homogeneous research methodology would likely allow for better consistency and reproducibility, which is of utmost importance in guiding evidence-based care.

show abstract

Efficacy of Pregabalin for Peripheral Neuropathic Pain: Results of an 8-Week, Flexible-Dose, Double-Blind, Placebo-Controlled Study Conducted in China

Cited by 58 publications

References 15 publications

A Randomized, Double‐blind, Placebo‐controlled Trial to Evaluate the Efficacy and Safety of Pregabalin for Postherpetic Neuralgia in a Population of Chinese Patients

A Randomized, Double‐blind, Placebo‐controlled Trial to Evaluate the Efficacy and Safety of Pregabalin for Postherpetic Neuralgia in a Population of Chinese Patients

Pregabalin in Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy

Alternatives to Opioids in the Pharmacologic Management of Chronic Pain Syndromes: A Narrative Review of Randomized, Controlled, and Blinded Clinical Trials

Contact Info

Product

Resources

About